Programmed death ligand 1 as an indicator of pre-existing adaptive immune responses in human hepatocellular carcinoma

Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma

(2015) M. Vassilakopoulou et al.   CLINICAL CANCER RESEARCH

Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade

(2015) J. M. Taube et al.   CLINICAL CANCER RESEARCH

PD-L1 expression in small cell neuroendocrine carcinomas

(2015) Anne M. Schultheis et al.   EUROPEAN JOURNAL OF CANCER

Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches

(2015) Tim F Greten et al.   GUT

The yin and yang of evasion and immune activation in HCC

(2015) Oxana V. Makarova-Rusher et al.   JOURNAL OF HEPATOLOGY

Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma

(2015) Yuki Katsuya et al.   LUNG CANCER

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

(2015) Christina Twyman-Saint Victor et al.   NATURE

Immunological landscape and immunotherapy of hepatocellular carcinoma

(2015) Jesús Prieto et al.   Nature Reviews Gastroenterology & Hepatology

CD14+macrophage-like cells as the linchpin of cervical cancer perpetrated immune suppression and early metastatic spread: A new therapeutic lead?

(2015) A Marijne Heeren et al.   OncoImmunology

PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics

(2014) D. Massi et al.   ANNALS OF ONCOLOGY

Unvalidated antibodies and misleading results

(2014) David Rimm et al.   BREAST CANCER RESEARCH AND TREATMENT

Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma

(2014) M. Atefi et al.   CLINICAL CANCER RESEARCH

In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas

(2014) K. A. Schalper et al.   CLINICAL CANCER RESEARCH

Immune checkpoint blockade in hepatocellular carcinoma: Current progress and future directions

(2014) Tai Hato et al.   HEPATOLOGY

Prognostic impact of programmed cell death 1 ligand 1 expression in human leukocyte antigen class I-positive hepatocellular carcinoma after curative hepatectomy

(2014) Yuichiroh Umemoto et al.   JOURNAL OF GASTROENTEROLOGY

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma

(2013) S. Lyford-Pike et al.   CANCER RESEARCH

PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies

(2013) B. J. Chen et al.   CLINICAL CANCER RESEARCH

Immunodominance and functional alterations of tumor-associated antigen-specific CD8+T-cell responses in hepatocellular carcinoma

(2013) Tobias Flecken et al.   HEPATOLOGY

Programmed death ligand-1 expression in non-small cell lung cancer

(2013) Vamsidhar Velcheti et al.   LABORATORY INVESTIGATION

Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines

(2013) A Q Butt et al.   ONCOGENE

Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells

(2013) S. Spranger et al.   Science Translational Medicine

PD-L1 Expression in the Merkel Cell Carcinoma Microenvironment: Association with Inflammation, Merkel Cell Polyomavirus, and Overall Survival

(2013) E. J. Lipson et al.   Cancer Immunology Research

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

(2012) J. M. Taube et al.   Science Translational Medicine

Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma

(2011) Valerie Chew et al.   GUT

Comparative analysis of various tumor-associated antigen-specific t-cell responses in patients with hepatocellular carcinoma

(2011) Eishiro Mizukoshi et al.   HEPATOLOGY

The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM

(2010) Stephen B. Edge et al.   ANNALS OF SURGICAL ONCOLOGY

Kupffer Cell Suppression of CD8+ T Cells in Human Hepatocellular Carcinoma Is Mediated by B7-H1/Programmed Death-1 Interactions

(2009) K. Wu et al.   CANCER RESEARCH

Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma

(2009) Q. Gao et al.   CLINICAL CANCER RESEARCH

Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1

(2009) Dong-Ming Kuang et al.   JOURNAL OF EXPERIMENTAL MEDICINE

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology